[Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl)]
- PMID: 169168
- DOI: 10.1507/endocrine1927.51.3_129
[Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl)]
Abstract
The present study was undertaken to clarify the mechanism of the diabetogenic activity of streptozotocin. Experiments were conducted to determine the resistance of animals to the diabetogenic action of streptozotocin; to follow the time course of irreversible beta-cell damage, and to determine the influence on streptozotocin action of certain compounds. Streptozotocin, a broad spectrum antibiotic, with antitumoral properties, was shown to be diabetogenic in rats and mice, but not in cats, rabbits, or guinea pigs. Intravenous or intraperitoneal administration of 65 mg/kg body weight of streptozotocin to male Wistar rats evoked a tri-phasic blood sugar response. It induced an initial hyperglycemic peak with no apparent change in plasma insulin concentrations, followed by profound hypoglycemia caused by liberation of large amounts of insulin from the pancreas. Forty-eight hours after injection, the animals were completely diabetic. Light- and electron-microscopic exadminations during the first forty-eight hours after the injection of streptozotocin showed pyknosis, degranulation and marked degeneration of the beta-cells. 1egenerative and necrotic changes were also seen in a few alpha-cells. These streptozotocin-induced diabetic rats revealed polydipsia, polyuria, polyphagia and glucosuria, and decreased body weight. Blood sugar, plasma FFA and insulin concentrations were examined after oral administration of glucose (OGTT: 3g/kg). Blood sugar and plasma FFA were significantly elevated but plasma insulin concentrations were markedly decreased, so insulin treatments were most effective in these animals. It has been reported that nicotinamide prevents the diabetogenic activity of streptozotocin and the deformity action of 6-aminonicotinamide and 3-acetylpridine. Pre-treatment with picolinamide, methyl-nicotinamide, and nicotinohydroxamic acid also blocked its diabetogenic action, but nicotinic acid, mannoheptulose and glucose were ineffective. N-nitrosodimethylamin and ethyl-N-nitrosomethylcarbamate were devoid of diabetogenicity. It seems that streptozotocin interfers with NAD formation in the beta-cell. Functioning pancreatic islets cell tumors were observed on the rats both at 407 days after streptozotocin administration and at 473 days after streptozotocin administration with nicotinamide (500 mg/kg, i.p.).
Similar articles
-
Biochemical studies on rats with insulin-secreting islet cell tumors induced by streptozotocin: with special reference to physiological response to oral glucose load in the course of and after tumor induction.Endocrinology. 1978 Nov;103(5):1541-5. doi: 10.1210/endo-103-5-1541. Endocrinology. 1978. PMID: 218781
-
Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide.J Clin Invest. 1974 Sep;54(3):672-7. doi: 10.1172/JCI107805. J Clin Invest. 1974. PMID: 4369217 Free PMC article.
-
Studies on streptozotocin diabetes.Diabetes. 1976 Jul;25(7):595-603. doi: 10.2337/diab.25.7.595. Diabetes. 1976. PMID: 132382
-
Streptozotocin-induced functioning islet cell tumor in the rat: high frequency of induction and biological properties of the tumor cells.Toxicol Pathol. 1984;12(3):274-80. doi: 10.1177/019262338401200311. Toxicol Pathol. 1984. PMID: 6151238
-
[Streptozotocin].Arzneimittelforschung. 1972 May;22(5):830-61. Arzneimittelforschung. 1972. PMID: 4340253 Review. German. No abstract available.
Cited by
-
Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.J Alzheimers Dis. 2009;17(3):519-29. doi: 10.3233/JAD-2009-1070. J Alzheimers Dis. 2009. PMID: 19363256 Free PMC article. Review.
-
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.J Alzheimers Dis. 2009;17(4):827-44. J Alzheimers Dis. 2009. PMID: 20387270 Free PMC article.
-
Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration.BMC Endocr Disord. 2010 Mar 19;10:4. doi: 10.1186/1472-6823-10-4. BMC Endocr Disord. 2010. PMID: 20302640 Free PMC article.
-
Brain metabolic dysfunction at the core of Alzheimer's disease.Biochem Pharmacol. 2014 Apr 15;88(4):548-59. doi: 10.1016/j.bcp.2013.12.012. Epub 2013 Dec 28. Biochem Pharmacol. 2014. PMID: 24380887 Free PMC article. Review.
-
Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.Mol Neurodegener. 2009 Dec 24;4:54. doi: 10.1186/1750-1326-4-54. Mol Neurodegener. 2009. PMID: 20034403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous